“Most Favored Nation” Implementation Expands Dangerous CMMI Authority

The Council for Citizens Against Government Waste (CCAGW) has issued a strong condemnation of the Center for Medicare and Medicaid Innovation's (CMMI) new 'most favored nation' drug price control model, asserting it will fail to reduce costs and stifle pharmaceutical innovation. CCAGW cited CMMI's track record of disrupting patient care, lacking transparency, and wasting $5.4 billion from 2011-2020 as reasons for its opposition. The organization is urging Congress to implement greater oversight and prevent the implementation of this 'deeply flawed' proposal.

Analysis

The Council for Citizens Against Government Waste (CCAGW) has issued a strongly negative assessment of the Center for Medicare and Medicaid Innovation's (CMMI) new "most favored nation" drug price control model. CCAGW asserts this policy, which imports price controls from countries with socialized medicine, will ultimately fail to reduce prices, stifle pharmaceutical innovation, and prove detrimental to taxpayers. This stance reflects a pessimistic outlook on the policy's efficacy and broader market implications.

CCAGW's opposition is rooted in CMMI's historical performance, citing a track record of disrupting patient and provider care, operating without adequate transparency, and wasting $5.4 billion between 2011 and 2020. The organization argues that integrating this "abysmal track record" with new price controls represents a deeply flawed approach that will exacerbate existing inefficiencies and financial waste.

The lobbying group is actively urging Congress to review CMMI's funding and establish meaningful guardrails, highlighting significant public support for increased oversight. A national survey conducted by CCAGW in October 2025 indicated that 76% of voters support expanded oversight of CMMI, while only 29% believe its $10 billion-per-decade budget is an appropriate use of taxpayer dollars, suggesting potential political pressure for intervention.

Key Decisions for Investors

• Monitor legislative developments regarding CMMI's authority and potential congressional intervention, as this could significantly alter the regulatory landscape for pharmaceutical pricing
• Investors should assess pharmaceutical companies' exposure to government-mandated price controls and their R&D pipelines for resilience against potential innovation stifling
• Consider re-evaluating long-term growth projections for companies heavily reliant on drug pricing power in the U.S. market